9.130USD-1.40%Mkt Cap: —P/E: —1d ago
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prul…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value-8.35M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-98.97M $
Revenue/Share—
Last Price9.130 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees102
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS0070021086
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA0.09
EV/Revenue—
P/S—
P/B0.81
EPS (TTM)-1.05
EPS (Forward)—
52W Range
8.90033% of range9.600
52W High9.600 USD
52W Low8.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-78.08%
ROA-41.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.53M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-105.34M $
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity10.70
Current Ratio6.71
Quick Ratio6.59
Book Value/Sh11.16 USD
Cash/Share10.98 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.0625:1
Split DateDec 30, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.28.05M
Float7.44M
Insiders1.08%
Institutions64.91%
Technical
SMA 502.635 (+246.5%)
SMA 2002.951 (+209.4%)
Beta1.59
S&P 52W Chg20.80%
Avg Vol (30d)127
Avg Vol (10d)2.28K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—